कंपनी का अवलोकन
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical entity primarily engaged in identifying novel targets for cancer drug development and the subsequent development and commercialization of cancer therapies. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at advancing medical treatments. Regarding its scale, Lixte Biotechnology Holdings, Inc. currently holds a market capitalization of $33.69M, while its annual revenue is listed as N/A and its employee count is also N/A. These valuation figures indicate that the company operates as a small-cap entity with limited historical financial data available for public analysis, suggesting a firm in the early stages of commercialization where revenue generation has not yet been fully realized or reported in the TTM period. The absence of reported employee data further contextualizes the company's current operational footprint, which is likely heavily weighted toward research and development rather than large-scale commercial infrastructure.
वित्तीय स्वास्थ्य
The company reports a net income of $-6,078,593 over the trailing twelve-month period, whereas its revenue and EBITDA are listed as N/A, indicating that traditional profitability metrics are not currently applicable due to the pre-revenue or early revenue stage of operations. The significant gap between reported revenue and net income, combined with the lack of revenue data, reveals a cost structure dominated by research and development expenditures that exceed current cash inflows. Lixte Biotechnology Holdings, Inc. generates free cash flow of $-1,278,703, which signifies a consumption of cash reserves necessary to fund ongoing clinical trials and operational expenses before achieving positive cash flow. Analyzing the three margins provided, the gross margin stands at 0.0%, the operating margin at 0.0%, and the profit margin at 0.0%, indicating that the company has not yet established a profitable revenue model or that sales are insufficient to cover the direct costs of goods sold and operating expenses. In terms of liquidity, the company holds cash of $5.11M against total debt of $1.03M, resulting in a debt-to-equity ratio of 9.44, which suggests a highly leveraged balance sheet relative to equity but a net cash position when considering absolute debt levels. The current ratio is 3.88, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer for immediate operational needs despite the negative free cash flow. Furthermore, the return on equity is -102.0% and the return on assets is -46.0%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic for clinical-stage biotechnology companies prioritizing asset growth over shareholder distribution.
मूल्यांकन आकलन
The trailing P/E ratio is N/A and the forward P/E is also N/A, implying that traditional earnings-based valuation methods are not applicable and that the market is pricing the stock based on potential future earnings rather than current profitability. The price-to-book ratio is 3.22, which indicates that the market is valuing the company at a significant premium over its tangible book value, reflecting the potential value of its intangible assets such as intellectual property and clinical data. The price-to-sales ratio and EV/EBITDA are both listed as N/A, suggesting that alternative valuation metrics typically used for mature companies are not yet relevant for this clinical-stage entity. Regarding price metrics, the 52-week high is $6.26 and the 52-week low is $0.64, meaning the stock has experienced extreme volatility within this trading range over the past year. The beta value is 0.95, which indicates that the stock's price volatility is roughly in line with the broader market, showing no significant deviation in risk profile relative to the overall market index.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue growth due to the lack of historical comparative data. As a non-dividend payer, Lixte Biotechnology Holdings, Inc. has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests all available earnings and cash reserves into research and development rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's life cycle stage, where capital is required to advance clinical trials for its lead product candidate, LB-100, rather than returning capital to investors. In summary, the overall growth and income profile is defined by a focus on capital appreciation and product development potential rather than current dividend income or established revenue growth trajectories.